A !https://jamanetwork.com/journals/jamasurgery/fullarticle/2811162 demonstrated a transdermal local delivery of the tamoxifen metabolite over a breast with DCIS, while achieving a nearly 10x lower serum concentration and slashing the potential for systemic side effects, unfortunately resulted in a relative decline in tumor Ki-67 of only 17% compared to 48% in the standard oral tamoxifen arm. | Khan, JAMA Surg 2023
